tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
PremiumThe FlyAnnovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
1M ago
Annovis Bio Hosts Regulation FD Investor Information Webinar
Premium
Company Announcements
Annovis Bio Hosts Regulation FD Investor Information Webinar
2M ago
Annovis Bio reports open-label extension study for Parkinson’s disease patients
Premium
The Fly
Annovis Bio reports open-label extension study for Parkinson’s disease patients
3M ago
Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress
PremiumRatingsAnnovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress
4M ago
Annovis Bio Inc. Reports Q3 2025 Financial Results
Premium
Company Announcements
Annovis Bio Inc. Reports Q3 2025 Financial Results
4M ago
Annovis Bio reports Q3 EPS (37c) vs. (97c) last year
Premium
The Fly
Annovis Bio reports Q3 EPS (37c) vs. (97c) last year
4M ago
Annovis Bio prices 1.67M shares at $2.05 in registered direct offering
PremiumThe FlyAnnovis Bio prices 1.67M shares at $2.05 in registered direct offering
5M ago
Annovis Bio Announces $6M Stock Offering
Premium
Company Announcements
Annovis Bio Announces $6M Stock Offering
5M ago
Promising Potential of Annovis Bio’s Buntanetap in Alzheimer’s Treatment Justifies Buy Rating
Premium
Ratings
Promising Potential of Annovis Bio’s Buntanetap in Alzheimer’s Treatment Justifies Buy Rating
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100